.jpg)
.jpg)
.jpg)
01 Apr, 2020
Gilead Sciences Announced Licensing of Portfolio of HIV Antibodies
Gilead Sciences, Inc. (NASDAQ: GILD) announced Thursday that it has licensed The Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074. These inve..
Lilly Shares Drop As Cancer Therapy Lartruvo Fails Study
Eli Lilly & Co. (NYSE: LLY) said on Friday its cancer treatment Lartruvo, approved on an accelerated basis in 2016, failed to improve patient survival in a long-term study and will no longer be prescribed, driving shares down 3%.The Company said..
@Newsletter
Sign Up for Weekly UpdatesOpt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!
No articles found.
.jpg){kind=small}
All rights reserved.
No portion of Financialinsiders.com may be duplicated, redistributed or manipulated in any form without our consent, violators will be prosecuted to the full extent of the law. By accessing any information beyond this page, you agree to abide by the Privacy Policy and Terms of Use (Disclaimer).